CN1625550A - 制备有机化合物的方法 - Google Patents

制备有机化合物的方法 Download PDF

Info

Publication number
CN1625550A
CN1625550A CNA038028778A CN03802877A CN1625550A CN 1625550 A CN1625550 A CN 1625550A CN A038028778 A CNA038028778 A CN A038028778A CN 03802877 A CN03802877 A CN 03802877A CN 1625550 A CN1625550 A CN 1625550A
Authority
CN
China
Prior art keywords
formula
unsubstituted
aralkyl
lower alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038028778A
Other languages
English (en)
Chinese (zh)
Inventor
G-P·陈
P·K·卡帕
E·M·勒泽尔
U·博伊特勒
W·佐格
M·J·吉尔吉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1625550A publication Critical patent/CN1625550A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)
CNA038028778A 2002-01-28 2003-01-27 制备有机化合物的方法 Pending CN1625550A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35231602P 2002-01-28 2002-01-28
US60/352,316 2002-01-28
US38318802P 2002-05-24 2002-05-24
US60/383,188 2002-05-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB200510005170XA Division CN100378081C (zh) 2002-01-28 2003-01-27 制备有机化合物的方法
CN200910139815A Division CN101654434A (zh) 2002-01-28 2003-01-27 制备有机化合物的方法

Publications (1)

Publication Number Publication Date
CN1625550A true CN1625550A (zh) 2005-06-08

Family

ID=27669055

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038028778A Pending CN1625550A (zh) 2002-01-28 2003-01-27 制备有机化合物的方法
CNB200510005170XA Expired - Lifetime CN100378081C (zh) 2002-01-28 2003-01-27 制备有机化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB200510005170XA Expired - Lifetime CN100378081C (zh) 2002-01-28 2003-01-27 制备有机化合物的方法

Country Status (19)

Country Link
US (3) US6835838B2 (enExample)
EP (1) EP1472227B1 (enExample)
JP (1) JP2005516064A (enExample)
KR (2) KR20100091267A (enExample)
CN (2) CN1625550A (enExample)
AU (4) AU2003239294B2 (enExample)
BR (1) BR0307236A (enExample)
CA (1) CA2472340A1 (enExample)
CO (1) CO5601045A2 (enExample)
EC (1) ECSP045202A (enExample)
IL (1) IL162817A0 (enExample)
MX (1) MXPA04007308A (enExample)
NO (1) NO327363B1 (enExample)
NZ (3) NZ554366A (enExample)
PL (1) PL371383A1 (enExample)
RU (1) RU2360903C2 (enExample)
SG (2) SG161742A1 (enExample)
WO (1) WO2003064382A2 (enExample)
ZA (1) ZA200405239B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218210B (zh) * 2005-07-08 2011-08-03 阿斯利康(英国)有限公司 罗苏伐他汀的制备方法和中间体
CN108976168A (zh) * 2017-06-02 2018-12-11 浙江京新药业股份有限公司 一种匹伐他汀半钙盐新晶型及其制备方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
PT1466905E (pt) 2001-11-14 2011-07-14 Nissan Chemical Ind Ltd Processo para a produção de éster do ácido oxo-heptenóico opticamente activo
DE60326819D1 (de) * 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
EP1539698B1 (en) * 2002-09-20 2010-10-20 Nissan Chemical Industries, Ltd. Method for producing a 3,5-dihydroxy-6-heptenoate
EP3299359A1 (en) 2003-02-12 2018-03-28 Nissan Chemical Industries, Ltd. Crystalline and amorphous forms of pitavastatin hemicalcium salt
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN1763015B (zh) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
SI2086945T1 (sl) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2010089770A2 (en) * 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
RU2425034C1 (ru) * 2010-01-11 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения производных (e)-4-(6,7-диметокси-2-метил-3-хинолил)-3-бутен-2-она
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
US9034901B2 (en) 2010-08-25 2015-05-19 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP2638013A4 (en) * 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
WO2012140490A2 (en) 2011-04-11 2012-10-18 Aurobindo Pharma Limited Process for preparing quinoline derivative
CN103755568B (zh) * 2013-12-10 2015-10-28 江西科技师范大学 IeodomycinA和B立体选择性合成方法
JP6704916B2 (ja) 2015-08-05 2020-06-03 株式会社エーピーアイ コーポレーション ピタバスタチンカルシウムの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JP3554036B2 (ja) * 1994-09-06 2004-08-11 宇部興産株式会社 光学活性な７−置換キノリル−３，５−ジヒドロキシ−ヘプト−６−エン酸エステル誘導体の製造方法
PT1466905E (pt) * 2001-11-14 2011-07-14 Nissan Chemical Ind Ltd Processo para a produção de éster do ácido oxo-heptenóico opticamente activo
EP2125754B1 (en) * 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218210B (zh) * 2005-07-08 2011-08-03 阿斯利康(英国)有限公司 罗苏伐他汀的制备方法和中间体
CN108976168A (zh) * 2017-06-02 2018-12-11 浙江京新药业股份有限公司 一种匹伐他汀半钙盐新晶型及其制备方法
CN108976168B (zh) * 2017-06-02 2020-09-25 浙江京新药业股份有限公司 一种匹伐他汀半钙盐晶型及其制备方法

Also Published As

Publication number Publication date
JP2005516064A (ja) 2005-06-02
CN100378081C (zh) 2008-04-02
US20030208072A1 (en) 2003-11-06
RU2004126448A (ru) 2005-06-27
KR20100091267A (ko) 2010-08-18
PL371383A1 (en) 2005-06-13
NO20043586L (no) 2004-10-07
CA2472340A1 (en) 2003-08-07
BR0307236A (pt) 2004-12-07
EP1472227A2 (en) 2004-11-03
SG157225A1 (en) 2009-12-29
NO327363B1 (no) 2009-06-15
AU2006225205A1 (en) 2006-10-26
NZ554367A (en) 2008-11-28
US7572917B2 (en) 2009-08-11
US20040249154A1 (en) 2004-12-09
RU2360903C2 (ru) 2009-07-10
MXPA04007308A (es) 2004-10-29
NZ534136A (en) 2007-08-31
ZA200405239B (en) 2005-07-27
US20090299065A1 (en) 2009-12-03
AU2009208129A1 (en) 2009-09-03
AU2006225206B2 (en) 2009-08-06
CN1660818A (zh) 2005-08-31
NZ554366A (en) 2008-11-28
IL162817A0 (en) 2005-11-20
CO5601045A2 (es) 2006-01-31
AU2003239294B2 (en) 2006-10-19
KR20040077883A (ko) 2004-09-07
EP1472227B1 (en) 2016-04-27
SG161742A1 (en) 2010-06-29
WO2003064382A2 (en) 2003-08-07
US6835838B2 (en) 2004-12-28
AU2006225205B2 (en) 2009-08-06
ECSP045202A (es) 2004-09-28
AU2006225206A1 (en) 2006-10-26
WO2003064382A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
CN1625550A (zh) 制备有机化合物的方法
US20080032964A1 (en) Process for the synthesis of azetidinone
CN1798741A (zh) 改进的罗苏伐他汀钙盐的制备方法
AU2003239294A1 (en) Process for the manufacture of organic compounds
CN1146760A (zh) α-卤代酮、α-卤代醇和环氧化物的制备方法
CN1015256B (zh) 取代的苯基丁烯酰胺化合物的制备方法
CN1040440C (zh) 去氢环黄皮酰胺衍生物的制备方法
CN88103507A (zh) 具有苯并噻唑或其它杂环支链的氧代-2，3-二氮杂萘基乙酸的制备方法
CN1130361C (zh) 异噁唑烷二酮化合物的制备方法
CN1662484A (zh) 制备(r)芳氧基丙酸酯衍生物的方法
CN1886371A (zh) 氟伐他汀钠多晶型物的制备方法
CN1255121A (zh) 制备药用化合物的选择性环氧化的方法
CN100347179C (zh) 经口给药用碳青霉素烯化合物的新的合成中间体及其制造方法
JP2010533208A (ja) 第三アルコールの製造方法
CN1812959A (zh) 制备二氟乙酰乙酸烷基酯的方法
CN1160350C (zh) 制备手性内酯的方法
CN1362948A (zh) 3s－3－氨基－3－芳基丙酸及其衍生物的制备方法
CN1630646A (zh) 旋光性吡咯衍生物及其制造方法
CN1084742C (zh) 3－苯基－1－亚甲二氧基苯基－1,2－二氢化茚－2－羧酸衍生物的制备方法
CN1653061A (zh) 喹诺酮羧酸衍生物的制备方法
CN1898229A (zh) 四氢吡喃－4－酮以及吡喃－4－酮的制备方法
CN1087084A (zh) 新的异丁基取代的甲磺酰基-喹啉基甲氧基苯基-环烷基乙酰胺
KR20080095476A (ko) 베타-메틸아제티디논의 제조방법
CN1290247A (zh) 制备抗叶酸剂的方法和中间体
CN86106583A (zh) 抗菌素的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20050608